Iconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has collaboration agreement with the French biotechnology company Affilogic, ENA Respiratory Pty Ltd, and Stevanato Group, as well as licensing agreements with Kiox Pharma and Monash University. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.
| 5 | |
| 4.71 | |
| - | |
| 4.64 | |
| 5.11 | |
| 4.15-12.55 | |
| 82 139 K | |
| 15 918 K | |
| 24 987 K | |
| -0.7001 | |
| 0.749 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Europeiska Patentorganisationen, EPO, har meddelat att de avser att godkänna (Intention to Grant) ett patent avseende Iconovos inhalatorplattform, ICOone. Iconovo har sedan tidigare två godkända sv...
Iconovos blivande VD, Johan Wäborg, har idag tecknat 200 000 teckningsoptioner i enlighet med beslut fattat på extra bolagsstämma den 11 mars 2020. Betalningen för optionerna uppgår till 1 224 ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
